Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease

Hepatology Research

Volumn 43, Issue 11, 2013, Pages 1163-1168

  Arase, Yasuji ^a   Kawamura, Yusuke ^a   Seko, Yuya ^a   Kobayashi, Mariko ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Akuta, Norio ^a   Kobayashi, Masahiro ^a   Sezaki, Hitomi ^a   Saito, Satoshi ^a   Hosaka, Tetsuya ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a   Ohmoto Sekine, Yuki ^a   Hsieh, Shiun Dong ^a   Amakawa, Kazuhisa ^a   Ogawa, Kyoko ^a   Matsumoto, Naoki ^a   Iwao, Akiko ^a   Tsuji, Hiroshi ^a   Hara, Shigeko ^a   Mori, Yasumichi ^a   Okubo, Minoru ^a   Sone, Hirohito ^a,b   Kobayashi, Tetsuro ^c   more..

^a TORANOMON HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Non alcoholic fatty liver disease; Sitagliptin; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; SITAGLIPTIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER FIBROSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84886828887     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12077     Document Type: Article

References (28)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 46: 1221-1231.
2. Williams R. Global changes in liver disease. Hepatology 2006; 44: 521-526.
3. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-1698.
4. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317.
5. Fan JC, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-210.
6. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008; 43: 509-518.
7. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46 (Suppl 1): 63-69.
8. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007; 46: 716-722.
9. van der Poorten D, Milner KL, Hui Jetal. Visceral fat a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-457.
10. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
11. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005; 54: 333-339.
12. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004; 39: 909-914.
13. Kheirandish-Gozal L, Sans Capdevila O, Kheirandish E, Gozal D. Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. Chest 2008; 133: 92-99.
14. Arase Y, Suzuki F, Kobayashi Metal. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 2011; 50: 1081-1087.
15. Ogawa K, Ohmoto Y, Hara Setal. New development of coronary heart disease and cerebral stroke in Japanese elderly patients with nonalcoholic fatty liver diseases. Ningen Dock 2012; 27: 561-567.
16. Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol 2009; 44: 1064-1070.
17. Kimura Y, Hyogo H, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol 2011; 26: 517-522.
18. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev 2007; 65: S57-63.
19. Kawamura Y, Ikeda K, Arase Yetal. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol 2008; 23: 1739-1746.
20. Arase Y, Kobayashi M, Suzuki F etal. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res 2012; 42: 264-272.
21. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
22. Vincent SH, Reed JR, Bergman AJ etal. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007; 35: 533-538.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl 1): S62-69.
24. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010; 53: 450-467.
25. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
26. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
27. Arase Y, Suzuki F, Kobayashi M etal. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol Res 2011; 41: 524-529.
28. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.